Offering the Appropriate Patient the Opportunity for Treatment with TRK Inhibitors

Ezra Cohen, MD, FRCPSC, FASCO; Mary Jo Fidler, MD; Arturo Loaiza-Bonilla, MD, MSEd, FACP

Video Categories: NTRK Gene Fusions

Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss who may and may not be appropriate candidates for TRK inhibitor therapy.

November 19, 2014

Costs of Treatment in Polycythemia Vera

Ken Schaecher, MD, presents his own personal opinion on the challenges of concerns related to costs of treatment by oncologists and why they should not ignore them. Supported through funding from Incyte

December 3, 2013

The Impact of Hedgehog Pathway Inhibitors on the Management of Patients with Basal Cell Carcinoma

In this third WCMC clinical commentary entitled, Basal Cell Carcinoma Case Studies in Hedgehog Pathway Inhibition Radiation, Joel Claveau, MD, CSPQ, FRCPC; Dirk Schadendorf, MD; Nicole Basset-Seguin, MD, PhD and Aleksandar Sekulic, MD, PhD discuss different case studies where patients were successfully treated by Hedgehog Pathway Inhibitors.